Clinical trials
Recruiting Obesity trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,151 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 10 |
| 2016 | 11 |
| 2017 | 5 |
| 2018 | 9 |
| 2019 | 23 |
| 2020 | 24 |
| 2021 | 39 |
| 2022 | 55 |
| 2023 | 116 |
| 2024 | 184 |
| 2025 | 314 |
| 2026 | 327 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 1,151 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 35 |
| Eli Lilly and Company | 23 |
| University of Colorado, Denver | 15 |
| Mayo Clinic | 12 |
| Assistance Publique - Hôpitaux de Paris | 10 |
| Cairo University | 10 |
| Columbia University | 9 |
| Istituto Auxologico Italiano | 9 |
| Laval University | 9 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 9 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Obesity | 1,151 |
| Overweight | 448 |
| Diabetes Mellitus, Type 2 | 136 |
| Weight Loss | 106 |
| Diabetes Mellitus | 70 |
| Insulin Resistance | 66 |
| Metabolic Syndrome | 64 |
| Hypertension | 52 |
| Cardiovascular Diseases | 46 |
| Prediabetic State | 38 |
Trials
Showing 51 to 75 of 1,151. Each trial links to its page on Pharma Observatory.
1,051 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.